We are live on ! Find out more
ABI

Adamant Biomedical Investments Portfolio holdings

AUM $418M Turnover 17.59%
This Fund
S&P 500
This Quarter Est. Return
+10.95%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$418M
AUM Growth
+$17.7M
Cap. Flow
-$20M
Cap. Flow %
-4.77%
Top 10 Hldgs %
32.81%
Holding
108
New
12
Increased
10
Reduced
35
Closed
7
Avg Time Held
0.2 years
Top 10 Avg Time Held
0.2 years
Top 20 Avg Time Held
0.2 years

Sector Composition

Rank Sector Weight
1 Healthcare 91.31%
2 Miscellaneous 7.35%
3 Financials 0.93%
4 Industrials 0.35%
5 Technology 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
CELG
1
DELISTED
Celgene
CELG
$20.8M 4.98%
186,170
-20,550
-10% -$2.17M
2014 Q3
1 quarter
BIIB icon
2
Biogen
BIIB
$37.2B
$18.1M 4.32%
53,250
-1,770
-3% -$573K
2014 Q3
1 quarter
GILD icon
3
Gilead Sciences
GILD
$208B
$17M 4.06%
180,390
-16,000
-8% -$1.65M
2014 Q3
1 quarter
AMGN icon
4
Amgen
AMGN
$250B
$15.1M 3.62%
95,000
-5,000
-5% -$779K
2014 Q3
1 quarter
AGN
5
DELISTED
Allergan plc
AGN
$13.3M 3.17%
51,590
-520
-1% -$130K
2014 Q3
1 quarter
UNH icon
6
UnitedHealth
UNH
$369B
$11.6M 2.78%
115,000
-13,000
-10% -$1.23M
2014 Q3
1 quarter
VTRS icon
7
Viatris
VTRS
$23.8B
$11.3M 2.69%
200,000
-30,000
-13% -$1.61M
2014 Q3
1 quarter
CTRX
8
DELISTED
Catamaran Corp
CTRX
$10.7M 2.57%
206,820
+70,080
+51% +$3.29M
2014 Q3
1 quarter
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
$10.5M 2.52%
57,000
-3,000
-5% -$556K
2014 Q3
1 quarter
MDT icon
10
Medtronic
MDT
$132B
$8.77M 2.1%
121,500
-28,500
-19% -$1.98M
2014 Q3
1 quarter
VRTX icon
11
Vertex Pharmaceuticals
VRTX
$136B
$8.67M 2.07%
73,000
– –
2014 Q3
1 quarter
REGN icon
12
Regeneron Pharmaceuticals
REGN
$98.5B
$8.62M 2.06%
21,000
+3,000
+17% +$1.18M
2014 Q3
1 quarter
MCK icon
13
McKesson
MCK
$128B
$8.51M 2.03%
41,000
– –
2014 Q3
1 quarter
CYTO icon
14
DELISTED
Altamira Therapeutics Ltd
CYTO
$8.46M 2.02%
27
– –
2014 Q3
1 quarter
MNK
15
DELISTED
Mallinckrodt
MNK
$7.92M 1.89%
80,000
– –
2014 Q3
1 quarter
ABT icon
16
Abbott
ABT
$186B
$7.79M 1.86%
173,000
-27,000
-14% -$1.18M
2014 Q3
1 quarter
AGN
17
DELISTED
Allergan Inc
AGN
$7.44M 1.78%
35,000
– –
2014 Q3
1 quarter
ILMN icon
18
Illumina
ILMN
$29.9B
$7.38M 1.76%
41,120
-3,084
-7% -$543K
2014 Q3
1 quarter
ACAD icon
19
Acadia Pharmaceuticals
ACAD
$3.23B
$6.51M 1.56%
205,000
+170,000
+486% +$4.82M
2014 Q3
1 quarter
MDVN
20
DELISTED
Medivation
MDVN
$6.48M 1.55%
130,000
+90,000
+225% +$4.68M
2014 Q3
1 quarter
CAH icon
21
Cardinal Health
CAH
$65.6B
$6.46M 1.54%
80,000
-25,000
-24% -$1.97M
2014 Q3
1 quarter
IONS icon
22
Ionis Pharmaceuticals
IONS
$4.66B
$6.17M 1.48%
100,000
-40,000
-29% -$1.97M
2014 Q3
1 quarter
AKRX
23
DELISTED
Akorn Inc
AKRX
$5.79M 1.38%
160,000
+100,000
+167% +$3.86M
2014 Q3
1 quarter
LLY icon
24
Eli Lilly
LLY
$1.28T
$5.52M 1.32%
80,000
– –
2014 Q3
1 quarter
HSP
25
DELISTED
Hospira
HSP
$5.51M 1.32%
+90,000
New +$5.08M
2014 Q4
0 quarters

Similar funds

Adamant Biomedical Investments's Q4 2014 Portfolio in Review

As of Q4 2014, Adamant Biomedical Investments held 108 positions worth $418M, up 4.4% from $401M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Adamant Biomedical Investments withdrew a net $20M in Q4 2014, closing 7 positions and reducing 35 holdings. Its most notable exit was Insulet, an estimated $2.95M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 89% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Adamant Biomedical Investments opened a new position in Hospira worth $5.51M.

  • Adamant Biomedical Investments's largest Q4 2014 buy was Hospira: 90,000 shares worth $5.51M.
  • Adamant Biomedical Investments added most to Acadia Pharmaceuticals in Q4 2014, an estimated $4.82M increase.
  • Adamant Biomedical Investments's biggest Q4 2014 reduction was Covidien, cutting an estimated $4.8M.
  • Adamant Biomedical Investments fully exited Insulet in Q4 2014, selling an estimated $2.95M.
  • Adamant Biomedical Investments's ten largest holdings make up 33% of its $418M portfolio in Q4 2014.
  • Adamant Biomedical Investments opened 12 new positions and closed 7 in Q4 2014.
  • Adamant Biomedical Investments's portfolio value rose 4.4% quarter-over-quarter to $418M.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.